Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
Celltrion Healthcare is expanding its presence in the United States, the world's largest pharmaceutical market, with its biosimilar of Avastin for metastatic colorectal and breast cancer, known as Vegzelma (active ingredient: bevacizumab).On Dec. 12, Celltrion Healthcare announced that Vegzelma was
Samsung Biologics and Celltrion have made it to the top 10 of the World’s Most Trusted Healthcare Companies, a list jointly compiled by the American weekly magazine Newsweek and global market research firm Statista.According to Newsweek on Sept. 8, Samsung Biologics secured the second position in th
Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Av
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Celltrion Healthcare’s OP for 3Q22 satisfied consensus if stripping out one-off costs. We see 2022E OP of W283.9bn, driven by Remsima IV/SC sales growth in the US and EU markets. If it mainly targets
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Lower TP to KRW200,000, but maintain BUY We lower our TP for Celltrion from KRW230,000 to KRW200,000 as we reflect downward revisions to 2022E/2023E OP of 10.4%/12.9% in light of a decline in margins following
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Maintain BUY but lower target price to KRW230,000 We lower our TP for Celltrion from KRW280,000 to KRW230,000, as we revise down 2022E/2023E OP by 10.9%/9.7% to reflect changes to WACC (8.08%→8.11%), risk-free
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. At the 2021 ASCO, Oscotec’s Lazertinib was presented as achieving an ORR of 90% in IHC-positive biomarkers for Tagrisso-resistant patients. MedPacto showed off superior data (compared to global pharm
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. 1) Rituximab biosimilar M/S: Truxima 21.9% vs. Ruxience 17.8%According to the US biosimilar prescription data for October, Celltrion’s Rituximab biosimilar Tru
The author is an analyst of KB Securities. She can be reached at kahye.hong@kbfg.com. -- Ed. Initiate coverage with BUY and target price of KRW340,000 We initiate coverage of Celltrion with a BUY rating and TP of KRW340,000. Our DCF-derived TP (50.5x 2021 P/E) reflects 6.04% WACC (6.04% cost of equi
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Samsung Biologics’ 1Q20 OP beat consensus by 46.2% thanks to rising utilization rates and reduced SG&A expenses. We raise our TP to reflect revised DCF valuation assumptions. We maintain a Buy ra
The author is an analyst with NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. With higher global demand for biosimilars and healthy earnings at global leading bio CDMO players translating into accompanying share price hikes, we believe that the time is ripe for a need to
The domestic biotech industry has been growing rapidly in recent years. Since 2016, Korea's biopharmaceuticals exports have surpassed imports. Biopharmaceuticals are pharmaceuticals made from materials derived from human or other organisms. Examples are biologics, genetically modified drugs, cel
Samsung Bioepis and Celltrion are competing to become the first Korean company to develop a biosimilar to “Avastin,” a blockbustger drug for colorectal cancer developed by global pharmaceutical company Roche.The two companies previously competed over the development of a biosimilar to “Herceptin,” a
According to industry sources, multinational pharmaceutical companies are hindering the growth of the global biosimilar market by using their patents.AbbVie’s Humira has been the best-selling medicine in the world for years and the American pharmaceutical company recorded US$16 billion in sales last
The number of approvals given to South Korean biosimilar clinical trials has surpassed that of multinational pharmaceutical companies.13 (in 10 items) out of the 25 biosimilar clinical trials (in 22 items) currently in progress are conducted by domestic companies. The number of approvals given clini
Samsung Bioepis Co., Ltd. announced on May 24 that the U.S. Food and Drug Administration (FDA) has accepted the review of its Biologics License Application (BLA) for SB2, a biosimilar candidate referencing Remicade® (infliximab), for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative
Celltrion, one of South Korea’s leading biotechnology companies, has recently revealed a contour of its future strategy for the biosimilar business, targeting the global market.Celltrion has reportedly decided to make clinical trials of biosimilars for Avastin and Humira this year, which will repres
With the smartphone and display sectors showing signs of market saturation the early 2010s, the Samsung Group has chosen the biopharmaceutical sector as one of the growth engines that the group is focusing on for the future.The biopharmaceutical market in general is expected to grow as large as the
Showing unprecedented development speed, Samsung has succeeded in developing all biosimilars of the global three autoimmune disorder treatments, including of Humira, the best selling drug in the world.Samsung Bioepis, a biotech subsidiary of the Samsung Group, announced on July 6 that the global Pha